Washout Duration of Prostaglandin Analogues: A Systematic Review and Meta-analysis

Vlad Diaconita, Matthew Quinn, Dania Jamal, Brad Dishan, Monali S Malvankar-Mehta, Cindy Hutnik, Vlad Diaconita, Matthew Quinn, Dania Jamal, Brad Dishan, Monali S Malvankar-Mehta, Cindy Hutnik

Abstract

Topic: Prostaglandin analogues (PGAs) are first-line medical therapy for primary open angle glaucoma (POAG) and ocular hypertension (OHT). Intraocular pressure (IOP) lowering effects in full responders are known to be 25-33% for this class; however, partial responders and nonresponders do exist. In clinical trials or prospective series, discontinuation and washout of PGAs is necessary to evaluate true change in IOP from novel surgeries and medical therapies.

Clinical relevance: To identify all relevant papers with pertinent data on washout of PGAs and quantify the duration and long-term effect of reported PGA washout periods in glaucoma and OHT patients.

Methods: A systematic review and meta-analysis was conducted to investigate the long-term effects on IOP after discontinuation of topical PGAs POAG and OHT patients. The main search was conducted in MEDLINE/PubMed, EMBASE, Cochrane Library, CINAHL, Web of Science, and BIOSIS Previews and conference proceedings.

Results: 1055 papers were identified, 548 were independently screened by two physicians., and 56 papers were analyzed for washout durations. The mean washout was found to be 4.56 weeks (±1.25), with the mode and median being 5 weeks. Five studies were analyzed as randomized control trials in which latanoprost was discontinued for 4 weeks prior to restarting another intraocular pressure-lowering drug. Meta-analysis revealed a 4-week discontinuation of latanoprost, on average, subjects returned to their baseline IOP.

Conclusion: A significant IOP-lowering effect of latanoprost was not observed beyond 4 weeks, suggesting this may be an appropriate washout period for latanoprost. We could not identify appropriate washout periods for either travoprost or bimatoprost, although a majority of articles had 4-week washout durations for the two drugs. Despite the widespread use of this class of medication, there is a paucity of literature on the effects of PGA washout in patients that are treatment naïve to other topical medications.

Figures

Figure 1
Figure 1
Inclusion and exclusion algorithm for screening articles.
Figure 2
Figure 2
Prisma 2009 flow diagram.
Figure 3
Figure 3
Washout duration of prostaglandin analogues and prostamides in research studies 1996–2016 (n = 56). Mean = 4.56 weeks; SD = 1.25; median = 4 weeks; mode = 4 weeks.
Figure 4
Figure 4
Visual inspection of funnel plot for both pre- and postwashout IOP (Figure 4) did not reveal any asymmetry.
Figure 5
Figure 5
Forest plot of 5 studies of latanoprost washout.

References

    1. Camras C. B., Alm A., Watson P., Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost study groups. Ophthalmology. 1996;103(11):1916–1924.
    1. Higginbotham E. J., Schuman J. S., Goldberg I., et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Archives of Ophthalmology. 2002;120(10):1286–1293. doi: 10.1001/archopht.120.10.1286.
    1. Canadian Opthalmology Association. Canadian ophthalmological society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Canadian Journal of Ophthalmology. 2009;44:S7–S54. doi: 10.3129/i09.080.
    1. Alm A. PhXA34, a new potent ocular hypotensive drug. Archives of Ophthalmology. 1991;109(11):1564–1568. doi: 10.1001/archopht.1991.01080110100045.
    1. Ziai N., Dolan J. W., Kacere R. D., Brubaker R. F. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes. Archives of Ophthalmology. 1993;111(10):1351–1358. doi: 10.1001/archopht.1993.01090100059027.
    1. Alm A., Stjemschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morn- ing: a comparison with timolol. Ophthalmology. 1995;102(12):1743–1752.
    1. Camras C. B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States latanoprost study group. Ophthalmology. 1996;103(1):138–147. doi: 10.1016/S0161-6420(96)30749-5.
    1. Mishima H. K., Masuda K., Kitazawa Y., Azuma I. A. M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension A 12-week study. Archives of Ophthalmology. 1996;114(8):929–932. doi: 10.1001/archopht.1996.01100140137004.
    1. Watson P., Stjernschantz J., Beck L., et al. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology. 1996;103(1):126–137. doi: 10.1016/s0161-6420(96)30750-1.
    1. Gandolfi S., Simmons S. T., Sturm R., Chen K., VanDenburgh A. M. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Advances in Therapy. 2001;18(13):110–121. doi: 10.1007/bf02850299.
    1. Noecker R. S., Dirks M. S., Choplin N. T., Bernstein P., Batoosingh A. L., Whitcup S. M. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. American Journal of Ophthalmology. 2003;135(1):55–63. doi: 10.1016/s0002-9394(02)01827-5.
    1. Stewart W. C., Day D. G., Stewart J. A., Schuhr J., Latham K. E. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. American Journal of Ophthalmology. 2001;131(5):631–635. doi: 10.1016/s0002-9394(00)00902-8.
    1. Stewart W. C., Holmes K. T., Johnson M. A. Washout periods for brimonidine 0.2% and latanoprost 0.005% American Journal of Ophthalmology. 2001;131(6):798–799. doi: 10.1016/s0002-9394(00)00930-2.
    1. Jampel H. D., Chon B. H., Stamper R., et al. Effectiveness of intraocular pressure-lowering medication determined by washout. JAMA Ophthalmology. 2014;132(4):390–395. doi: 10.1001/jamaophthalmol.2013.7677.
    1. Giuffrè G. The effects of prostaglandin F2a in the human eye. Graefe’s Archive for Clinical and Experimental Ophthalmology. 1985;222(3):139–141. doi: 10.1007/bf02173538.
    1. Downs S. H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. Journal of Epidemiology and Community Health. 1998;52(6):377–384. doi: 10.1136/jech.52.6.377.
    1. Malvankar-Mehta M. S., Chen Y., Iordanous Y., Wang W., Hutnik C. iStent as a solo procedure for glaucoma patients: a systematic review and meta-analysis. PLoS One. 2015;10(5) doi: 10.1371/journal.pone.0128146.e0128146
    1. Aung T., Chew P. T., Yip C. C., et al. A randomized double-masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open-angle glaucoma and ocular hypertension. American Journal of Ophthalmology. 2001;131(5):636–642. doi: 10.1016/s0002-9394(00)00943-0.
    1. Kobayashi H. Efficacy of single glaucoma medication in combined latanoprost and timolol xe therapy in patients with open-angle glaucoma and ocular hypertension: a discontinuation study. Journal of Ocular Pharmacology and Therapeutics. 2012;28(4):387–391. doi: 10.1089/jop.2011.0127.
    1. Larsson L. I. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension. Ophthalmology. 2001;108(8):1439–1444. doi: 10.1016/s0161-6420(01)00605-4.
    1. Linden C., Nuija E., Alm A. Effects on IOP restoration and blood-aqueous barrier after long-term treatment with latanoprost in open angle glaucoma and ocular hypertension. British Journal of Ophthalmology. 1997;81(5):370–372. doi: 10.1136/bjo.81.5.370.
    1. Sehi M., Grewal D. S., Feuer W. J., Greenfield D. S. The impact of intraocular pressure reduction on retinal ganglion cell function measured using pattern electroretinogram in eyes receiving latanoprost 0.005% versus placebo. Vision Research. 2011;51(2):235–242. doi: 10.1016/j.visres.2010.08.036.
    1. Sit A. J., Weinreb R. N., Crowston J. G., Kripke D. F., Liu J. H. K. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. American Journal of Ophthalmology. 2006;141(6):1131–1133. doi: 10.1016/j.ajo.2006.01.049.
    1. Walters T. R., DuBiner H. B., Carpenter S. P., Khan B., VanDenburgh A. M. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: A 1-month, randomized, comparative clinical trial. Survey of Ophthalmology. 2004;49(2):S26–S35. doi: 10.1016/j.survophthal.2003.12.017.
    1. Dubiner H. B., Sircy M. D., Landry T., et al. comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clinical Therapeutics. 2004;26(1):84–91. doi: 10.1016/s0149-2918(04)90008-2.
    1. Kurtz S., Shemesh G. The efficacy and safety of once-daily versus once-weekly latanoprost treatment for increased intraocular pressure. Journal of Ocular Pharmacology and Therapeutics. 2004;20(4):321–327. doi: 10.1089/1080768041725353.
    1. Kass M., Johnson C. A., Keltner J. L., Miller J. P., Ii R. K. P., Wilson M. R. The ocular hypertension treatment study. Journal of Glaucoma. 1994;120
    1. Egger M., Smith G. D., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi: 10.1136/bmj.315.7109.629.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir